Home Antibody All anti-F13A1 antibodies
Anti-F13A1 TRUEMAB Antibody Clone 1C9
TrueMAB Antibodies - Made against Authentic Protein Antigens
Also for F13A1 (NM_000129)
|Full length human recombinant protein of human F13A1 (NP_000120) produced in HEK293T cell.|
|| WB 1:2000,
|PBS (PH 7.3) containing 1% BSA, 50% glycerol and 0.02% sodium azide.|
|Purified from mouse ascites fluids by affinity chromatography
|Homo sapiens coagulation factor XIII, A1 polypeptide (F13A1)|
Entrez Gene 2162 Human
|This gene encodes the coagulation factor XIII A subunit. Coagulation factor XIII is the last zymogen to become activated in the blood coagulation cascade. Plasma factor XIII is a heterotetramer composed of 2 A subunits and 2 B subunits. The A subunits have catalytic function, and the B subunits do not have enzymatic activity and may serve as plasma carrier molecules. Platelet factor XIII is comprised only of 2 A subunits, which are identical to those of plasma origin. Upon cleavage of the activation peptide by thrombin and in the presence of calcium ion, the plasma factor XIII dissociates its B subunits and yields the same active enzyme, factor XIIIa, as platelet factor XIII. This enzyme acts as a transglutaminase to catalyze the formation of gamma-glutamyl-epsilon-lysine crosslinking between fibrin molecules, thus stabilizing the fibrin clot. It also crosslinks alpha-2-plasmin inhibitor, or fibronectin, to the alpha chains of fibrin. Factor XIII deficiency is classified into two categories: type I deficiency, characterized by the lack of both the A and B subunits; and type II deficiency, characterized by the lack of the A subunit alone. These defects can result in a lifelong bleeding tendency, defective wound healing, and habitual abortion. [provided by RefSeq, Jul 2008]. |
|Secreted ProteinDruggable Genome Complement and coagulation cascades|
* Availability is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY F13A1 (RC206464, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-F13A1.